Post-authorization safety study in patients with type 2 diabetes mellitus to assess the incidence of ketoacidosis, severe complications of urinary tract infection, volume depletion, and dehydration among patients treated with EMPAGLIFLOZIN or DPP-4 inhibitors in Saudi Arabia

drug protocol number
1245/149
drug sponsor
Boehringer Ingelheim
drug study
Jardiance
drug trial site
Armed Force Hospital (Al-Hada), King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase